RET Inhibitor Biomarker Information - Learn More

PIPELINE > TRIAL OVERVIEW

Type of Alteration(s)

Point Mutations^*

Alteration(s) of Interest ^†

RET M918T

Sanger Sequencing

Lower sensitivity than NGS for somatic alterations, thus more suitable for germline testing in MTC
Detection may require higher tumor content than PCR-based assays

PCR-based

NGS (Tissue)

Suitable for broad-based genomic profiling that includes targets in addition to RET

NGS (cfDNA)

Point mutations occur in MTC, and gene fusions occur in PTC and NSCLC

†

List is not exhaustive of all activating alterations

References

Type of Alteration(s)

Gene fusions^*

Alteration(s) of Interest ^†

KIF5B-RET
CCDC6-RET
NCOA4-RET

NGS (cfDNA)

Sanger Sequencing

Lower sensitivity than NGS for somatic alterations, thus more suitable for germline testing in MTC
Detection may require higher tumor content than PCR-based assays

NGS (Tissue)

Suitable for broad-based genomic profiling that includes targets in addition to RET
RNA-based NGS is most suitable for fusions

PCR-based

FISH

Lack of standard cutoffs to define positivity
Close proximity of common fusion partners can complicate analysis
Cannot determine if fusion results in functional protein, leading to false positives

Gene fusions occur in PTC and NSCLC, point mutations occur in MTC

†

List is not exhaustive of all activating alterations

References

For information on trial enrollment, locations, and more, call 1-800-545-5979.

or visit www.clinicaltrials.gov for more information on this trial